Prevention of erlotinib-induced folliculitis with doxycycline

Affiliations

Comment

Emi Dika et al. Dermatol Ther. 2017 Jan.

. 2017 Jan;30(1).

doi: 10.1111/dth.12419. Epub 2016 Sep 4.

¹ Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

No abstract available

Comment on

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
Deplanque G, Gervais R, Vergnenegre A, Falchero L, Souquet PJ, Chavaillon JM, Taviot B, Fraboulet G, Saal H, Robert C, Chosidow O; CYTAR investigators. Deplanque G, et al. J Am Acad Dermatol. 2016 Jun;74(6):1077-85. doi: 10.1016/j.jaad.2016.01.019. Epub 2016 Mar 4. J Am Acad Dermatol. 2016. PMID: 26946985 Clinical Trial.